2019
DOI: 10.1246/cl.190179
|View full text |Cite
|
Sign up to set email alerts
|

Organometallic Iridium Arene Compounds: The Effects ofC-Donor Ligands on Anticancer Activity

Abstract: Rianne M. Lord obtained her Ph.D. degree in chemistry in 2014 under the supervision of Professor Patrick C. McGowan at the University of Leeds (U.K.). Following this, she joined the research team of Professor Polly L. Arnold at the University of Edinburgh (U.K.) as a postdoctoral research associate. In 2016, Rianne began her independent career as a lecturer of bioinorganic chemistry at the University of Bradford (U.K.) and currently holds an August-Wilhelm Scheer visiting professorship at the Technische Univer… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
26
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 28 publications
(27 citation statements)
references
References 117 publications
1
26
0
Order By: Relevance
“…There is a need for the development and screening of anticancer therapeutics with non-conventional mechanisms of action (MoAs) [ 2 , 3 , 4 ]. Metallodrugs can provide rich chemistry and unique MoAs owing to their versatile structures, geometries and reactivities: examples include polypyridyl octahedral complexes of precious metals, some of which have been shown to target mitochondria and generate high levels of reactive oxygen species (ROS), while others can act as photosensitisers for use in photodynamic therapy [ 5 , 6 , 7 , 8 , 9 , 10 , 11 ], and half-sandwich complexes of metals from groups eight and nine (Fe, Ru, Os; Co, Rh, Ir) [ 12 , 13 , 14 , 15 , 16 , 17 , 18 ]. In this context, the binding of bioactive ligand(s) to metal fragments is of interest since this strategy may lead to the release of at least two biologically active species, therefore potentially offering enhanced activity against resistant cancer cells [ 19 , 20 , 21 , 22 , 23 , 24 , 25 ].…”
Section: Introductionmentioning
confidence: 99%
“…There is a need for the development and screening of anticancer therapeutics with non-conventional mechanisms of action (MoAs) [ 2 , 3 , 4 ]. Metallodrugs can provide rich chemistry and unique MoAs owing to their versatile structures, geometries and reactivities: examples include polypyridyl octahedral complexes of precious metals, some of which have been shown to target mitochondria and generate high levels of reactive oxygen species (ROS), while others can act as photosensitisers for use in photodynamic therapy [ 5 , 6 , 7 , 8 , 9 , 10 , 11 ], and half-sandwich complexes of metals from groups eight and nine (Fe, Ru, Os; Co, Rh, Ir) [ 12 , 13 , 14 , 15 , 16 , 17 , 18 ]. In this context, the binding of bioactive ligand(s) to metal fragments is of interest since this strategy may lead to the release of at least two biologically active species, therefore potentially offering enhanced activity against resistant cancer cells [ 19 , 20 , 21 , 22 , 23 , 24 , 25 ].…”
Section: Introductionmentioning
confidence: 99%
“…52,79 It has been well established that the metal centers, size of metal ions, ancillary ligands and the binding affinity with the target receptor proteins play essential roles in the anticancer activities of metal–organic compounds. 80 Comparative analysis of these fumarato bridged compounds reveals that the reported Zn( ii ) coordination polymer 79 viz. {[Zn 2 (μ-fum) 2 (Hdmpz) 4 ]·3H 2 O} n (where, fum = fumarate and Hdmpz = 3,5-dimethylpyrazole) showed relatively better cytotoxicity in DL cancer cell lines with an IC 50 value of 19.21 μM.…”
Section: Resultsmentioning
confidence: 99%
“…Subsequent reports allowed to delineate the structural parameters (charge, nature of the chelating ligand, degree of lability of the third ligand) governing their cytotoxicity. [8][9][10][11] For some complexes, a relationship between cytotoxicity and rapid raise of total intracellular reactive oxygen species (ROS) was highlighted 12 with concomitant upregulation of antioxidant responses. 13 More generally, the ability of molecules to modulate the oxidation stress represents an innovative strategy to preferentially target cancer cells owing to their unique metabolic properties.…”
Section: -6mentioning
confidence: 99%